ASCO Watch List - Glioblastoma Multiforme
Glioblastoma multiforme (grade IV astrocytoma, GBM) is a fast-growing type of central nervous system tumor that forms from supportive tissue of the brain and spinal cord (glia) (NCI Dictionary of Cancer Terms). The cure rate is very low with standard treatment, and several pharmas and biotechs have compounds in development in an effort to improve outcomes.
At ASCO 2008, investigators will report on studies with inhibitors of EGFR tyrosine kinase, mTOR, serine/threonine, topoisomerase I, and VEGFR; neutralizing monoclonal antibody to VEGF; and EGFR-targeted vaccine.
Seven compounds to watch:
AP 12009
AntiSense Pharma (Regensburg, Germany)
ClinicalTrials.gov
PubMed
ASCO 2008
enzastaurin (LY 317615)
Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ)
ClinicalTrials.gov
PubMed
ASCO 2008
Glivec (imatinib)
Novartis Pharmaceuticals (East Hanover, NJ)
ClinicalTrials.gov
PubMed
ASCO 2008
Tarceva (erlotinib)
Genentech (South San Francisco, CA)
ClinicalTrials.gov
PubMed
ASCO 2008
vatalanib (PTK 787)
Novartis Pharmaceuticals (East Hanover, NJ)
ClinicalTrials.gov
PubMed
ASCO 2008
Iressa (gefitinib)
AstraZeneca (Wilmington, DE)
ClinicalTrials.gov
PubMed
ASCO 2008
Sutent (sunitinib)
Pfizer (New York, NY)
ClinicalTrials.gov
PubMed
ASCO 2008
OncologyWatch: Posts about free-access articles on aspects of oncology theory, research, practice and policy (about the blogger).This blog is not a source for medical advice.
Technorati tags:
oncology cancer pharmaceutical industry glioblastoma multiforme
Comments and Links Welcome!
